Recursion Pharmaceuticals, Inc. Class A

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Nasdaq

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...
KRON4 News

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds ...
Finanznachrichten

Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...